Delving into the Latest Updates on Ivonescimab with Synapse

Overview

Basic Info

Drug Type

Bispecific antibody

Synonyms

ivonescimab, AK 112, AK-112

+ [4]

Target

PD-1 x VEGF-A

Action

inhibitors

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)

Therapeutic Areas

NeoplasmsRespiratory DiseasesDigestive System Disorders+ [8]

Active Indication

PD-L1 positive Non-Small Cell Lung CancerEGFR positive Non-squamous non-small cell lung cancerEGFR-mutated non-small Cell Lung Cancer+ [82]

Inactive Indication-

Originator Organization

Akeso Biopharma Co., Ltd.

Active Organization

Akeso Biopharma Co., Ltd.Summit Therapeutics, Inc.

Akeso Pharmaceuticals, Inc.

+ [4]

Inactive Organization-

License Organization

Shanghai Pharmaceutical Co., Ltd.

Virogin Biotech Ltd.

Akeso Biopharma Co., Ltd.

+ [5]

Drug Highest PhaseApproved

First Approval Date

China (21 May 2024),

EGFR positive Non-squamous non-small cell lung cancer

RegulationPriority Review (China), Breakthrough Therapy (China), Fast Track (United States)

Login to view timeline

Structure/Sequence

Sequence Code 41637

Source: *****

Sequence Code 616715490

Source: *****

This phase II Expanded Lung-MAP treatment trial compares how well sacituzumab govitecan alone, ivonescimab alone, or sacituzumab govitecan in combination with ivonescimab works in treating patients with non-small cell lung cancer (NSCLC) that has come back after a period of improvement (recurrent) or is stage IV and has a change in at least 1 of these genes: ALK, EGFR, HER2 (ERBB2), MET, NTRK, RET, and ROS1. This type of gene change is called an actionable genomic alteration (AGA), which means certain treatments can target the change to fight the cancer. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a toxic drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as TROP2 receptors, and delivers SN-38 to kill them. Ivonescimab is a bispecific antibody that can bind to two different antigens at the same time. It binds to programmed cell death protein 1 (PD1), a protein found on the surface of T cells (a type of white blood cell) and vascular endothelial growth factor (VEGF), a protein found on the surface of tumor cells. Ivonescimab may strengthen the immune system and interfere with the ability of tumor cells to grow and spread. Giving a combination of sacituzumab govitecan and ivonescimab work better than either drug alone, and sacituzumab govitecan alone, ivonescimab alone, or sacituzumab govitecan and ivonescimab together may work better than standard treatments at shrinking NSCLC with an AGA.

Start Date07 Aug 2026

Sponsor / Collaborator

SWOG

[+1]

NCT07405190

/ Not yet recruitingPhase 2IIT

A Phase II Study of Ivonescimab as Monotherapy or in Combination With Platinum/Pemetrexed Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring Actionable Genomic Alterations (AGAs)

The goal of this clinical trial is to assess the efficacy of ivonescimab monotherapy in patients with advanced non-small cell lung cancer harboring actionable genomic alterations who have received prior targeted therapies and chemotherapy. This clinical trial also aims to assess the efficacy of ivonescimab plus carboplatin/pemetrexed chemotherapy in patients with advanced non-small cell lung cancer harboring actionable genomic alterations other than epidermal growth factor receptor mutations who have received prior targeted therapies but no chemotherapy. The main questions it aims to answer are:
* Will ivonescimab alone or together with carboplatin/pemetrexed chemotherapy shrink tumors in the clinical trial's patients?
* Will ivonescimab alone or together with carboplatin/pemetrexed chemotherapy effectively influence if the patients' cancer grows, how long the treatment takes to start working, how long the treatment keeps working after it first starts to help, how long the treatment keeps the cancer from getting worse, and overall survival of patients?
* How many patients receiving ivonescimab alone or together with carboplatin/pemetrexed chemotherapy will experience treatment-emergent, treatment-related, immune-related, and especially interesting side effects? Patients receiving ivonescimab alone will receive an intravenous infusion of ivonescimab every 3 weeks for up to 24 months. Patients receiving ivonescimab together with carboplatin/pemetrexed chemotherapy will receive separate intravenous infusions of ivonescimab, pemetrexed, and carboplatin every 3 weeks for 4 cycles (each cycle is 21 days). These patients will continue to receive infusions of ivonescimab and pemetrexed every 3 weeks for up to 24 total months.

Start Date04 Aug 2026

Sponsor / Collaborator

The Massachusetts General Hospital

[+1]

NCT07363408

/ Not yet recruitingPhase 1IIT

A Phase I Clinical Trial of Ivonescimab and ADG126, Alone, and in Combination With 5-FU/LV or FOLFIRI in MSS Advanced/Metastatic Colorectal Cancer

This phase I trial studies the safety, side effects, and best dose of ADG126, in combination with ivonescimab alone, in combination with ivonescimab, leucovorin, and fluorouracil, or in combination with ivonescimab and leucovorin, fluorouracil, and irinotecan (FOLFIRI regimen) in treating patients with microsatellite stable (MSS) colorectal cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as ivonescimab and ADG126, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ivonescimab may also stop or slow the cancer by blocking the growth of new blood vessels necessary for tumor growth. Leucovorin calcium is a type of drug called a folic acid analog, which means it is similar to the vitamin folic acid. It is used in combination with certain chemotherapy drugs to enhance their ability to kill tumor cells or to lessen their harmful side effects. Fluorouracil is a type of chemotherapy called an antimetabolite, which is a drug that mimics a natural chemical and prevents its use in cells. It interferes with the production of a key component of deoxyribonucleic acid (DNA), which prevents the DNA from copying itself. This causes tumor cells and other rapidly dividing cells to die. Fluorouracil also gets incorporated into ribonucleic acid (RNA) and DNA, disrupting critical cell functions. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Giving ADG126 with ivonescimab, with or without leucovorin and fluorouracil or FOLFIRI regimen, may be safe in treating patients with MSS advanced/metastatic colorectal cancer.

Start Date21 Jul 2026

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

100 Clinical Results associated with Ivonescimab

Login to view more data

100 Translational Medicine associated with Ivonescimab

Login to view more data

100 Patents (Medical) associated with Ivonescimab

Login to view more data

47

Literatures (Medical) associated with Ivonescimab

01 Feb 2026·JOURNAL OF CONTROLLED RELEASE

The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors

Review

Author: Li, Jia-Ting ; Luo, Wei-Chi ; Chen, Zhi-Hong ; Wu, Lv ; Zhou, Qing ; Zhang, Yi-Chen

Resistance to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) presents a significant clinical challenge for patients with advanced EGFR-mutant non-small cell lung cancer. Resistance arises through diverse mechanisms, including on-target and off-target gene alterations and histologic transformation. Notably, in up to 50% of cases, the etiology of resistance remains unknown, underscoring the need for effective non-targeted systemic therapies. In recent years, multiple antibody-drug conjugates (ADCs) have been developed and evaluated in this setting, with trophoblast cell-surface antigen 2 ADCs recently receiving approval from the National Medical Products Administration and the Food and Drug Administration for use after EGFR-TKI resistance. This review comprehensively outlines the structural features of ADCs, clinical trial designs involving biomarker-selected and unselected patient populations, and the application of ADCs in clinical practice including novel combination strategies such as chemotherapy plus amivantamab or ivonescimab. Toxicity management is also summarized. Finally, the review discusses key challenges and future directions in ADC development across four aspects: optimizing ADC design through artificial intelligence and multi-omics; evaluating novel combination therapies; evolving from overcoming resistance to delaying or preventing resistance to third-generation EGFR-TKIs via patient selection and circulating tumor DNA guidance; and advancing personalized toxicity management.

02 Jan 2026·Future Oncology

Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1–positive non-small cell lung cancer in the HARMONi–2 study

Article

Author: Chen, Kai ; Ye, Feng ; Xu, Zhi ; Zhuo, Minglei ; Su, Wenzhong ; Chen, Hualin ; Zhou, Caicun ; Xie, Conghua ; Wang, Mengzhao ; Ma, Rui ; Zhang, Yan ; Shen, Hong ; Moore, Amy C. ; Zhang, Zhihong ; Chen, Enguo ; Wang, Lei ; Yao, Wenxiu ; Wu, Hongcheng ; Gan, Xin

31 Dec 2025·mAbs

Antibodies to watch in 2025

Review

Author: Kapoor, Vaishali ; Crescioli, Silvia ; Kaplon, Hélène ; Visweswaraiah, Jyothsna ; Reichert, Janice M. ; Wang, Lin

The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025. In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (®), and antibody-drug conjugate (ADC) sacituzumab tirumotecan (®). We also discuss 30 investigational antibody therapeutics for which marketing applications were undergoing review by at least one regulatory agency, as of our last update on December 9, 2024, including ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab deruxtecan, trastuzumab botidotin, becotatug vedotin, and trastuzumab rezetecan. Of 178 antibody therapeutics we include in the late-stage pipeline, we summarize key data for 18 for which marketing applications may be submitted by the end of 2025, such as bi- or multispecific antibodies denecimig, sonelokimab, erfonrilimab, and anbenitamab. Key trends in the development and approval of antibody formats such as bispecifics and ADCs, as well as clinical-phase transition and global approval success rates for these antibody formats, are reported.

334

News (Medical) associated with Ivonescimab

16 Mar 2026

·www.fiercepharma.com

J&J files trade secret lawsuit against former oncology employee linked to Summit Therapeutics

Johnson & Johnson claims a former associate director now employed by Summit Therapeutics downloaded more than 7,000 confidential internal documents to her personal device before and after her resignation. Johnson & Johnson is suing a former oncology medical affairs employee, alleging a massive and “malicious” stealing of trade secrets. According to a complaint filed March 12 in a federal court in New Jersey, J&J’s subsidiary Janssen Global Services claims that Cynthia Nwachukwu, a former associate director now “employed by” Summit Therapeutics, downloaded more than 7,000 confidential internal documents to her personal device in the months leading up to her departure from the company in November 2025.These files allegedly include sensitive brand strategies and research information such as reviews of market gaps, existing and future opportunities for assets, initiatives to support brand growth and positioning, proprietary documents to guide clinical trials and evidence generation—some of which predated her employment by more than a decade.Summit Therapeutics, which is seeking FDA approval for its PD-1xVEGF bispecific ivonescimab in EGFR-mutated non-small cell lung cancer, did not immediately respond to Fierce’s request for comment. In its complaint, J&J describes the Florida biotech as a “direct competitor.” During her time at J&J, Nwachukwu managed Rybrevant (amivantamab) and Lazcluze (lazertinib) in the same disease area.Nwachukwu joined J&J as an associate director of global medical affairs execution focused on lung cancer around November 2021, the complaint shows. In May 2025, Nwachukwu received a negative performance review, and her job security looked precarious as she was placed on a performance improvement plan two months later. A J&J forensic review found that Nwachukwu began transferring large volumes of internal documents to her personal device a few days after receiving negative work feedback. Of the over 7,000 documents she procured, more than 1,200 were downloaded after she began a leave of absence in October, the complaint says. These include over 700 after she tendered her resignation. Besides lung-related files, she also downloaded “highly confidential documents” related to certain J&J neuroscience and immunology products, according to the complaint. In an alleged effort to avoid detection, Nwachukwu reportedly “took affirmative steps” to conceal her tracks by deleting files from her personal account and immediately emptying the recycling bin.After her resignation, Nwachukwu listed Cynthera Precision Intelligence as her workplace on LinkedIn, with the title “founder & principal.” On her LinkedIn profile, Nwachukwu described Cynthera as a biopharma intelligence business, which J&J also considers as a direct competitor.The documents Nwachukwu holds provides her, Cynthera and Summit with “an unfair competitive advantage,” the J&J lawsuit claims.Before filing the lawsuit, J&J had communicated the alleged wrongdoing with Nwachukwu through their respective lawyers. In a response in December 2025, Nwachukwu denied any misconduct and claimed that the downloading was necessary when her work device was allegedly “impaired,” according to J&J’s complaint. However, the company found her device activity and communications around that time contradict that statement. J&J is demanding compensatory and punitive damages over the former staffer’s “willful, fraudulent and malicious conduct.” The pharma is also seeking injunctions to prevent the use of its proprietary data, plus relief that orders her to return or destroy the documents.The case again highlights the importance of competitive intelligence in the biopharma sector. In recent years, J&J has made similar accusations against former employees for misappropriating proprietary information and bringing them to competitors Pfizer and Noah Medical.

Drug ApprovalExecutive ChangePatent Infringement

10 Mar 2026

·endpoints.news

China is going after the world's most expensive drugs: Endpoints Signal

Gene therapies were supposed to be competition-proof. They are scientifically complex, require bespoke manufacturing, often go after small patient populations and can cost millions per dose. But that assumption is being tested by a wave of competitors being developed in China — with prices starting at a fraction of what’s currently available in the US. An Endpoints News analysis looked at the world’s 10 most expensive gene therapies and found 77 competitors in development around the world. Of those, 48 are from China — more than double the number under development in the US, and 7 times what’s being worked on in Europe. The development of these gene therapies is the latest piece of evidence that China is competing higher and higher on the spectrum of innovative science. In gene therapy, the concentration of Chinese challengers is striking across nearly every target. Zynteglo ($2.8 million per treatment), Elevidys ($3.2M), Roctavian ($2.9M) and Casgevy ($2.2M) each face seven or more Chinese challengers. Lenmeldy ($4.25M), the most expensive therapy on the list, has three competitors coming from China — and none from the US or Europe. The only chart-topping gene therapy for which the US or Europe has more competing treatments under development than China is Lyfgenia ($3.1M), for sickle cell disease. Even there, Chinese companies own more than a third of the competitive field under development. The pressure arrives at a vulnerable moment for Western-originated gene therapy work. BioMarin said on Feb. 24 that it would pull its struggling hemophilia A therapy Roctavian from the market after failing to find a buyer. Uptake of UniQure’s Hemgenix for hemophilia B has been slow, with only 75 patients receiving it in the first three years after its US approval , as of December. Other first-generation therapies have been mostly limited to wealthy countries or have underperformed clinically. And payers across the world continue to resist multi-million-dollar price tags for single-course treatments. The economics that were supposed to justify the steep prices of gene therapies — replacing a lifetime of chronic care with a single course of treatment — haven’t fully materialized. China’s cost advantage The regulatory path to first-in-human dosing is significantly faster in China. The time it takes to enroll patients in clinical trials there is half the global average, and the cost per patient is also about 50% lower, according to McKinsey . And China’s domestic pricing constraints force cost discipline. The first fully homegrown Chinese gene therapy , approved last April for hemophilia B, launched for about $350,000. That’s a tenth of the price of a rival gene therapy in the US. At least 34 Chinese drug developers have programs aimed at the top 10 therapies, with several running multiple simultaneous efforts across different disease targets. Shanghai Vitalgen BioPharma leads with five unique therapies in development. Shenzhen Geno-Immune Medical Institute has four. Belief BioMed, CorrectSequence Therapeutics and HuidaGene Therapeutics each have three. Outside of gene therapy, China already has a blockbuster: the blood-cancer pill Brukinsa from BeOne Medicines, now headquartered in Switzerland, with $3.9 billion in sales last year. It also has a potential giant slayer: Akeso’s Ivonescimab, the first drug to beat the global bestseller, Merck’s Keytruda, in a head-to-head Phase 3 trial . Almost half of the new drug molecules entering human testing now originate in China. Read more about the companies: Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans

Gene TherapyPhase 3Drug Approval

07 Mar 2026

·www.prnewswire.com

U.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China

SHANGHAI, March 6, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and Parkinson's disease using ivonescimab, a novel immunotherapy currently available only in China. Continue Reading Dr. Xuan Linli, Chief of Medical Oncology at Jiahui International Cancer Center, stands on the patient’s right. The patient’s daughter, nursing team, medical team, and caregivers are gathered together at Jiahui International Hospital. The 70‑something patient had exhausted all standard lines of treatment at MD Anderson Cancer Center in the United States. His doctors recommended ivonescimab, the first approved PD‑1/VEGF bispecific antibody for solid tumors. After a video consultation in late November scheduled within a week of their initial inquiry, the family chose Jiahui International Cancer Center in Shanghai for its multidisciplinary expertise and U.S.‑trained Medical Oncology Chief Dr. XUAN Linli. During treatment, the patient developed immune‑related complications requiring ICU care. The cancer center rapidly coordinated oncology, neurology, critical care, and expert input from ivonescimab principal investigator Dr. Zhou Caicun. His condition has since stabilized, with ongoing care focused on disease control. As a tertiary international hospital partnered with Massachusetts General Hospital Cancer Center, Jiahui provides seamless international patient pathways, from remote consultations to travel coordination and continuous family updates. The patient's daughter said, "We are deeply grateful for the dedication, compassion, and tireless efforts of the entire Jiahui team: the doctors, nurses, kitchen and cleaning staff, the international team and front desk, and the care aides. My father would especially like to express his heartfelt thanks to Ms. Cui, who has cared for him every day since his admission. Beyond her attentive bedside care, she has offered him encouragement, comfort, and hope." China's breakthrough oncology innovations are creating new options for patients worldwide. JICC continues to draw growing inquiries and referrals from North America, Europe, Asia and the Middle East, establishing Shanghai as a global hub for advanced cancer care. The full story: Contact: International Patient Services inter[email protected] WhatsApp: +852 4619 1904 SOURCE Jiahui International Hospital 21% more press release views with Request a Demo

ImmunotherapyDrug ApprovalClinical StudyCSCO

100 Deals associated with Ivonescimab

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
PD-L1 positive Non-Small Cell Lung Cancer	China	Akeso-Sino Pharma Co., Ltd.	22 Apr 2025
EGFR positive Non-squamous non-small cell lung cancer	China	Akeso-Sino Pharma Co., Ltd.	21 May 2024

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
EGFR-mutated non-small Cell Lung Cancer	NDA/BLA	United States	Summit Therapeutics, Inc.	12 Jan 2026
Advanced Lung Non-Small Cell Squamous Carcinoma	NDA/BLA	China	Akeso Pharmaceuticals, Inc.	25 Jul 2025
Advanced Lung Non-Small Cell Squamous Carcinoma	NDA/BLA	China	Akeso-Sino Pharma Co., Ltd.	25 Jul 2025
Squamous Cell Carcinoma of Head and Neck	Phase 3	-	Akeso Biopharma Co., Ltd.	01 Jan 2026
Non-Small Cell Lung Cancer	Phase 3	China	Akeso Biopharma Co., Ltd.	30 Jun 2025
Small Cell Lung Cancer	Phase 3	China	Akeso Biopharma Co., Ltd.	13 Jun 2025
Small cell lung cancer limited stage	Phase 3	China	Akeso Biopharma Co., Ltd.	13 Jun 2025
Metastatic Pancreatic Cancer	Phase 3	China	Akeso Biopharma Co., Ltd.	05 Jun 2025
Advanced Lung Non-Small Cell Carcinoma	Phase 3	-	Akeso Biopharma Co., Ltd.	01 Jun 2025
Adenocarcinoma of large intestine	Phase 3	China	Akeso Biopharma Co., Ltd.	27 May 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06940518 (IVORY, ASCO_GU2026)	Phase 2	Metastatic Clear Cell Renal Cell Carcinoma	40	Ivonescimab (no prior exposure to VEGF-directed agents)	wztkthalkr(ojtmsgzgqi) = unbdowvand zeldkhnjrx (qekhcoqwql )	Positive	26 Feb 2026
				Ivonescimab (previously received VEGF-directed therapy)	vtgkrjjxqr(kdouvtbxvy) = ohudaaestc rttszuofuc (ecglfmuqgv ) View more
NCT06718543 (TRIUNITE-03, ASCO_GI2026)	Phase 2	Locally Advanced Rectal Carcinoma Neoadjuvant	100	SCRT + Ivonescimab + CapeOX	btvhxxdhga(nbeijwuorg) = cekjdgtnct wgpvnppsvv (dqvzwexnws )	Positive	08 Jan 2026
				SCRT + Ivonescimab	ozllamprpi(geerbgyoix) = lwkuujexje xbbdnkdvfv (qanpmqqobm ) View more
NCT05227664 (ESMO_IO 12025 \| ESMO_IO 22025 \| PRNewswire) Manual	Phase 2	Triple Negative Breast Cancer PD-L1	36	Ivonescimab + paclitaxel or nab-paclitaxel	tfvliilfmo(qcpmizjknq) = lmyojpxayh spjwaiomdb (pwsfqdygtr ) View more	Positive	10 Dec 2025
				Ivonescimab + paclitaxel or nab-paclitaxel (PD-L1 CPS≥10)	tfvliilfmo(qcpmizjknq) = swcpylhcyj spjwaiomdb (pwsfqdygtr ) View more
SITC2025	Not Applicable	Brain Stem Glioma H3K27M+	1	Ivonescimab 10 mg/kg	ncniponllu(remztpbacw) = No Grade 3 or higher adverse events were observed during the treatment period, based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. hwtovuqwwp (cnzjgtolyl )	Positive	05 Nov 2025
NCT05840016 (HARMONi-6, Pubmed \| Lancet)	Phase 3	Squamous non-small cell lung cancer First line	532	Ivonescimab plus chemotherapy	oyxbxijjit(twbcklykti) = nwxfpyeden mwfuhbjgag (jhtetmuxye ) View more	Positive	01 Nov 2025
				Tislelizumab plus chemotherapy	oyxbxijjit(twbcklykti) = huwzccdnlg mwfuhbjgag (jhtetmuxye ) View more
NCT05840016 (HARMONi-6, ESMO2025) Manual	Phase 3	Squamous non-small cell lung cancer First line	532	Ivonescimab 20 mg/kg Q3W + paclitaxel (175 mg/m2) +carboplatin (AUC 5)	rpabvltyir(bthbtjpqpu) = wuocgaahwe iwbdinkycj (mdayeycskr ) View more	Positive	17 Oct 2025
				Tislelizumab 200 mg Q3W + paclitaxel (175 mg/m2) + carboplatin (AUC 5)	rpabvltyir(bthbtjpqpu) = kcduqxnqrg iwbdinkycj (mdayeycskr ) View more
NCT06375486 (ESMO2025)	Phase 2	Unresectable Hepatocellular Carcinoma First line	33	Ivonescimab 20 mg/kg	gqdayqfraz(rgzcnxcerb) = ypwztnllwl obszifvzzd (juorzcqewm ) View more	Positive	17 Oct 2025
				Ivonescimab 20 mg/kg (BCLC C subgroup)	gqdayqfraz(rgzcnxcerb) = bklzgvlklq obszifvzzd (juorzcqewm ) View more
NCT06396065 (HARMONi, WCLC2025 \| NEWS) Manual	Phase 3	EGFR positive non-small cell lung cancer EGFR Positive	438	Ivonescimab + pemetrexed + carboplatin	jdqttoowsu(tssbmgqjlz) = onzipkiegr rpargjbpcr (vdsugfqrsh, 5.7 - 7.1) Met View more	Positive	09 Sep 2025
				Placebo + pemetrexed + carboplatin	jdqttoowsu(tssbmgqjlz) = ihigvebzxy rpargjbpcr (vdsugfqrsh, 4.1 - 5.5) Met View more
NCT05184712 (HARMONi-A, NEWS) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer EGFR-mutated	-	ivonescimab + chemotherapy	jwvkcheniz(ppnxnhqimu) = the Phase III HARMONi-A trial met its OS goal, showing that ivonescimab. rnjwbyjdwt (ygvimcyohy ) Met	Positive	26 Aug 2025
				placebo + chemotherapy
NCT06396065 (HARMONi, NEWS 1 \| NEWS 2) Manual	Phase 3	Non-squamous non-small cell lung cancer \| EGFR positive Neoplasms Second line EGFR Mutation	-	ivonescimab +化疗	szbovylbcl(udfqmngpiu): 0.52 (95.0% CI, 0.41 - 0.66), P-Value = <0.00001 View more	Positive	30 May 2025
				化疗

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data